A. Neki

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes et al. · Journal of Clinical Oncology · 2024 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer

Tamila L. Kindwall‐Keller, Gregory A. Otterson, Donn C. Young et al. · Clinical Cancer Research · 2005 · 27 citations

Medicine, Oncology, Pharmacology +17

A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

Tanios Bekaii‐Saab, Alexander Starodub, Bassel F. El‐Rayes et al. · Journal of Clinical Oncology · 2017 · 17 citations

Medicine, Oncology, Pharmacology +17

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

Tanios Bekaii‐Saab, Alexander Starodub, Bassel F. El‐Rayes et al. · Journal of Clinical Oncology · 2018 · 16 citations

Medicine, Oncology, Pharmacology +17

Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma

C. Barney, Steve Walston, P. Zamora et al. · Oral Oncology · 2018 · 10 citations

Medicine, Oncology, Radiation Oncology +14